Treatment recommendations for DSM-5-defined mixed features

CNS Spectrums

Volumn 22, Issue 2, 2017, Pages 147-154

  Rosenblat, Joshua D ^a   Mcintyre, Roger S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotics; bipolar disorder; DSM 5; guidelines; lurasidone; major depressive disorder; mixed episode; mixed features; mixed states; mood stabilizers

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; CARIPRAZINE; CLOZAPINE; FLUOXETINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; LURASIDONE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VERAPAMIL; ZIPRASIDONE; LITHIUM CARBONATE; VALPROIC ACID;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL PRACTICE; COGNITIVE BEHAVIORAL THERAPY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DSM-5; DSM-IV; DSM-IV-TR; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; HAMILTON DEPRESSION RATING SCALE; HUMAN; HYPOMANIA; MAJOR DEPRESSION; MANIA; MONOTHERAPY; MOOD DISORDER; MORBIDITY; MORTALITY; PATIENT MONITORING; PREVALENCE; REVIEW; YOUNG MANIA RATING SCALE; COMORBIDITY; CONTROLLED STUDY; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUICIDE; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; LITHIUM CARBONATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUICIDE; TREATMENT OUTCOME; VALPROIC ACID;

EID: 84987654752     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852916000432     Document Type: Review

References (60)

1. Swann AC, Lafer B, Perugi G, et al. Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis. Am J Psychiatry. 2013; 170(1): 31-42.
2. Castle DJ. Bipolar mixed states: still mixed up?. Curr Opin Psychiatry. 2014; 27(1): 38-42.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text rev. Washington, DC: American Psychiatric Association; 1994.
4. Benvenuti A, Miniati M, Callari A, Giorgi Mariani M, Mauri M, DellOsso L. Mood spectrum model: evidence reconsidered in the light of DSM-5. World J Psychiatry. 2015; 5(1): 126-137.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
6. Kessing LV. The prevalence of mixed episodes during the course of illness in bipolar disorder. Acta Psychiatr Scand. 2008; 117(3): 216-224.
7. McIntyre RS, Soczynska JK, Cha DS, et al. The prevalence and illness characteristics of DSM-5-defined "mixed feature specifier" in adults with major depressive disorder and bipolar disorder: tesults from the International Mood Disorders Collaborative Project. J Affect Disord. 2015; 172: 259-264.
8. Verdolini N, Agius M, Ferranti L, Moretti P, Piselli M, Quartesan R. The state of the art of the DSM-5 "with mixed features" specifier. The Scientific World Journal. 2015; 2015: 757258.
9. Shim IH, Woo YS, Jun TY, Bahk WM. Mixed-state bipolar I and II depression: time to remission and clinical characteristics. J Affect Disord. 2014; 152-154: 340-346.
10. Undurraga J, Baldessarini RJ, Valenti M, Pacchiarotti I, Vieta E. Suicidal risk factors in bipolar I and II disorder patients. J Clin Psychiatry. 2012; 73(6): 778-782.
11. Shim IH, Woo YS, Bahk WM. Prevalence rates and clinical implications of bipolar disorder "with mixed features" as defined by DSM-5. J Affect Disord. 2015; 173: 120-125.
12. Popovic D, Vieta E, Azorin JM, et al. Suicide attempts in major depressive episode: evidence from the BRIDGE-II-Mix study. Bipolar Disord. 2015; 17(7): 795-803.
13. Seo HJ, Wang HR, Jun TY, Woo YS, Bahk WM. Factors related to suicidal behavior in patients with bipolar disorder: the effect of mixed features on suicidality. Gen Hosp Psychiatry. 2016; 39: 91-96.
14. 2015 Florida Best Practice Psychotherapeutic Medication Guidelines for Adults. 2015. http://medicaidmentalhealth.org/ViewGuideline.cfm?GuidelineID=97.
15. Woo YS, Lee JG, Jeong JH, et al. Korean Medication Algorithm Project for Bipolar Disorder: third revision. Neuropsychiatr Dis Treat. 2015; 11: 493-506.
16. Fagiolini A, Coluccia A, Maina G, et al. Diagnosis, epidemiology and management of mixed states in bipolar disorder. CNS Drugs. 2015; 29(9): 725-740.
17. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999; 318(7182): 527-530.
18. Lobban F, Solis-Trapala I, Symes W, Morriss R, ERP Group, University of Liverpool. Early warning signs checklists for relapse in bipolar depression and mania: utility, reliability and validity. J Affect Disord. 2011; 133(3): 413-422.
19. Hergueta T, Weiller E. Evaluating depressive symptoms in hypomanic and manic episodes using a structured diagnostic tool: validation of a new Mini International Neuropsychiatric Interview (M.I.N.I.) module for the DSM-5 With Mixed Features specifier. Int J Bipolar Disord. 2013; 1: 21.
20. Kessing LV, Hansen HV, Hvenegaard A, et al. Treatment in a specialised out-patient mood disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. Br J Psychiatry. 2013; 202(3): 212-219.
21. Bauer M, Juckel G, Correll CU, Leopold K, Pfennig A. Diagnosis and treatment in the early illness phase of bipolar disorders. Eur Arch Psychiatry Clin Neurosci. 2008; 258(Suppl 5): 50-54.
22. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar disord. 2013; 15(1): 1-44.
23. Schaffer A, Isometsa ET, Azorin JM, et al. A review of factors associated with greater likelihood of suicide attempts and suicide deaths in bipolar disorder: Part II of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder. The Aust N Z J Psychiatry. 2015; 49(11): 1006-1020.
24. Leonpacher AK, Liebers D, Pirooznia M, et al. Distinguishing bipolar from unipolar depression: the importance of clinical symptoms and illness features. Psychol Med. 2015; 45(11): 2437-2446.
25. Frankland A, Cerrillo E, Hadzi-Pavlovic D, et al. Comparing the phenomenology of depressive episodes in bipolar I and II disorder and major depressive disorder within bipolar disorder pedigrees. J Clin Psychiatry. 2015; 76(1): 32-38; quiz 39.
26. Benazzi F. Bipolar disorder-focus on bipolar II disorder and mixed depression. Lancet. 2007; 369(9565): 935-945.
27. Akiskal HS, Benazzi F. Family history validation of the bipolar nature of depressive mixed states. J Affect Disord. 2003; 73(1-2): 113-122.
28. Maj M, Pirozzi R, Magliano L, Fiorillo A, Bartoli L. Agitated "unipolar" major depression: prevalence, phenomenology, and outcome. J Clin Psychiatry. 2006; 67(5): 712-719.
29. Takeshima M, Oka T. Association between the so-called "activation syndrome" and bipolar II disorder, a related disorder, and bipolar suggestive features in outpatients with depression. J Affect Disord. 2013; 151(1): 196-202.
30. McMahon K, Herr NR, Zerubavel N, Hoertel N, Neacsiu AD. Psychotherapeutic treatment of bipolar depression. Psychiatr Clin North Am. 2016; 39(1): 35-56.
31. McIntyre RS, Tohen M, Berk M, Zhao J, Weiller E. DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data. J Affect Disord. 2013; 150(2): 378-383.
32. Tohen M, McIntyre RS, Kanba S, Fujikoshi S, Katagiri H. Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5. J Affect Disord. 2014; 168: 136-141.
33. Suppes T, Ketter TA, Gwizdowski IS, et al. First controlled treatment trial of bipolar II hypomania with mixed symptoms: quetiapine versus placebo. J Affect Disord. 2013; 150(1): 37-43.
34. McElroy SL, Martens BE, Creech RS, et al. Randomized, doubleblind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate-To-severe hypomania or mild mania. J Clin Psychiatry. 2010; 71(5): 557-565.
35. Muralidharan K, Ali M, Silveira LE, et al. Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: a meta-Analysis of placebo-controlled trials. J Affect Disord. 2013; 150(2): 408-414.
36. McIntyre RS, Yoon J. Efficacy of antimanic treatments in mixed states. Bipolar Disord. 2012; 14(Suppl 2): 22-36.
37. Fountoulakis KN, Kontis D, Gonda X, Siamouli M, Yatham LN. Treatment of mixed bipolar states. Int J Neuropsychopharmacol. 2012; 15(7): 1015-1026.
38. Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006; 163(2): 232-239.
39. Frye MA, Helleman G, McElroy SL, et al. Correlates of treatmentemergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry. 2009; 166(2): 164-172.
40. Cressman AM, Macdonald EM, Huang A, et al. Prescription stimulant use and hospitalization for psychosis or mania: a population-based study. J Clin Psychopharmacol. 2015; 35(6): 667-671.
41. Dundar Y, Greenhalgh J, Richardson M, Dwan K. Pharmacological treatment of acute agitation associated with psychotic and bipolar disorder: a systematic review and meta-Analysis. Hum Psychopharmacol. 2016; 31(4): 268-285.
42. Curtin F, Schulz P. Clonazepam and lorazepam in acute mania: a Bayesian meta-Analysis. J Affect Disord. 2004; 78(3): 201-208.
43. Durgam S, Earley W, Lipschitz A, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016; 173(3): 271-281.
44. Calabrese JR, Keck PE Jr, Starace A, et al. Efficacy and safety of lowand high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015; 76(3): 284-292.
45. Medda P, Toni C, Mariani MG, De Simone L, Mauri M, Perugi G. Electroconvulsive therapy in 197 patients with a severe, drugresistant bipolar mixed state: treatment outcome and predictors of response. J Clin Psychiatry. 2015; 76(9): 1168-1173.
46. Valenti M, Benabarre A, Garcia-Amador M, Molina O, Bernardo M, Vieta E. Electroconvulsive therapy in the treatment of mixed states in bipolar disorder. Eur Psychiatry. 2008; 23(1): 53-56.
47. Patkar A, Gilmer W, Pae CU, et al. A 6 week randomized doubleblind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS One. 2012; 7(4): e34757.
48. Pae CU, Patkar AA, Gilmer W, Holtzman N, Thommi SB, Ghaemi SN. Predictors of response to ziprasidone: results from a 6-week randomized double-blind, placebo-controlled trial for acute depressive mixed state. Pharmacopsychiatry. 2012; 45(4): 152-155.
49. Benazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. J Clin Psychiatry. 2009; 70(10): 1424-1431.
50. Tohen M, Kanba S, McIntyre RS, Fujikoshi S, Katagiri H. Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features. J Affect Disord. 2014; 164: 57-62.
51. McIntyre RS, Cucchiaro J, Pikalov A, Kroger H, Loebel A. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry. 2015; 76(4): 398-405.
52. Yatham LN, Paulsson B, Mullen J, Vagero AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol. 2004; 24(6): 599-606.
53. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005; 162(7): 1351-1360.
54. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009; 117(Suppl 1): S26-S43.
55. Suppes T, Silva R, Cucchiaro J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2016; 173 (4): 400-407.
56. Citrome L, Ketter TA, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2014; 155: 20-27.
57. McElroy SL, Keck PE Jr. Metabolic syndrome in bipolar disorder: a review with a focus on bipolar depression. J Clin Psychiatry. 2014; 75(1): 46-61.
58. McIntyre RS, Danilewitz M, Liauw SS, et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord. 2010; 126(3): 366-387.
59. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry. 2005; 66(Suppl 3): 28-36.
60. Goldstein BI, Carnethon MR, Matthews KA, et al. Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015; 132(10): 965-986.